SE460576B - Mot graensskiktspolymerisation med hjaelp av fosfolipid stabiliserad insulinpreparation - Google Patents

Mot graensskiktspolymerisation med hjaelp av fosfolipid stabiliserad insulinpreparation

Info

Publication number
SE460576B
SE460576B SE8206168A SE8206168A SE460576B SE 460576 B SE460576 B SE 460576B SE 8206168 A SE8206168 A SE 8206168A SE 8206168 A SE8206168 A SE 8206168A SE 460576 B SE460576 B SE 460576B
Authority
SE
Sweden
Prior art keywords
insulin
solution
solution according
carbon atoms
ineulin
Prior art date
Application number
SE8206168A
Other languages
English (en)
Swedish (sv)
Other versions
SE8206168L (sv
SE8206168D0 (sv
Inventor
P E Hansen
Brange J J Vejlgaard
S Havelund
Original Assignee
Novo Industri As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Industri As filed Critical Novo Industri As
Publication of SE8206168D0 publication Critical patent/SE8206168D0/xx
Publication of SE8206168L publication Critical patent/SE8206168L/xx
Publication of SE460576B publication Critical patent/SE460576B/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE8206168A 1981-10-30 1982-10-29 Mot graensskiktspolymerisation med hjaelp av fosfolipid stabiliserad insulinpreparation SE460576B (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK478681 1981-10-30
DK324782 1982-07-20

Publications (3)

Publication Number Publication Date
SE8206168D0 SE8206168D0 (sv) 1982-10-29
SE8206168L SE8206168L (sv) 1983-05-01
SE460576B true SE460576B (sv) 1989-10-30

Family

ID=26066963

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8206168A SE460576B (sv) 1981-10-30 1982-10-29 Mot graensskiktspolymerisation med hjaelp av fosfolipid stabiliserad insulinpreparation

Country Status (20)

Country Link
US (1) US4614730A (cs)
AT (1) AT382079B (cs)
AU (1) AU549593B2 (cs)
BE (1) BE894885A (cs)
CA (1) CA1198673A (cs)
CH (1) CH649922A5 (cs)
DE (1) DE3240177A1 (cs)
ES (1) ES8403025A1 (cs)
FI (1) FI80595C (cs)
FR (1) FR2515517B1 (cs)
GB (1) GB2107985B (cs)
GR (1) GR77360B (cs)
IE (1) IE54029B1 (cs)
IT (1) IT1153315B (cs)
LU (1) LU84447A1 (cs)
NL (1) NL193099C (cs)
NO (1) NO168086C (cs)
NZ (1) NZ202328A (cs)
PT (1) PT75766B (cs)
SE (1) SE460576B (cs)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4604376A (en) * 1982-04-21 1986-08-05 Research Corporation Enteric compounds and complexes
US4914084A (en) * 1984-05-09 1990-04-03 Synthetic Blood Corporation Composition and method for introducing heme, hemoproteins, and/or heme-hemoprotein complexes into the body
WO1985005029A1 (en) * 1984-05-09 1985-11-21 Medaphore Inc. Oral insulin and a method of making the same
DE3443877A1 (de) * 1984-06-09 1985-12-12 Hoechst Ag Insulinzubereitungen, verfahren zu deren herstellung und deren verwendung
CA1257199A (en) * 1986-05-20 1989-07-11 Paul Y. Wang Preparation containing bioactive macromolecular substance for multi-months release in vivo
FR2605449B1 (fr) * 1986-10-17 1988-12-02 Thomson Cgr Bloc magnetique a aimantation ajustable pour la production d'un champ magnetique permanent dans une zone d'interet
NZ222907A (en) * 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
US5179079A (en) * 1986-12-16 1993-01-12 Novo Nordisk A/S Nasal formulation and intranasal administration therewith
US5266310A (en) * 1987-09-17 1993-11-30 Boehringer Ingelheim International Gmbh Stabilization of therapeutically active proteins in pharmaceutical preparations
NZ228285A (en) * 1988-03-11 1991-08-27 Teikoku Seiyaku Kk Pharmaceutical composition comprising a polypeptide and adapted for intravaginal administration
US5725871A (en) * 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
GB9007052D0 (en) * 1990-03-29 1990-05-30 Skua Investments Ltd Pharmaceutical formulations
EP0525035B1 (en) * 1990-04-17 1996-07-03 Analytical Control Systems, Inc. Coagulation assays and reagents
DE4208552A1 (de) * 1992-03-17 1993-09-23 Liedtke Pharmed Gmbh Topische arzneiformen mit insulin
BR9507023A (pt) 1994-03-07 1997-09-23 Inhale Therapeutic Syst Processos para aerossolização de uma dose de insulina para a liberação respiratória de insulina e para preparação de uma composição de insulina e composição de insulina
US6214375B1 (en) 1996-07-16 2001-04-10 Generex Pharmaceuticals, Inc. Phospholipid formulations
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
US7070799B1 (en) * 1998-02-10 2006-07-04 Generex Pharmaceuticals, Inc. Method for administering insulin to the buccal region
US6221378B1 (en) 1998-02-10 2001-04-24 Generex Pharmaceuticals Incorporated Mixed micellar delivery system and method of preparation
US6017545A (en) * 1998-02-10 2000-01-25 Modi; Pankaj Mixed micellar delivery system and method of preparation
US6290987B1 (en) 1998-09-27 2001-09-18 Generex Pharmaceuticals, Inc. Mixed liposome pharmaceutical formulation with amphiphiles and phospholipids
US6849263B2 (en) * 1998-12-21 2005-02-01 Generex Pharmaceutical Incorporated Pharmaceutical compositions for buccal delivery of pain relief medications
US6436367B1 (en) 1998-12-21 2002-08-20 Generex Pharmaceuticals Inc. Aerosol formulations for buccal and pulmonary application
US6375975B1 (en) 1998-12-21 2002-04-23 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary application
US6451286B1 (en) 1998-12-21 2002-09-17 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary administration comprising an alkali metal alkyl sulfate and at least three micelle-forming compounds
US7087215B2 (en) * 1998-12-21 2006-08-08 Generex Pharmaceuticals Incorporated Methods of administering and enhancing absorption of pharmaceutical agents
US6271200B1 (en) 1998-12-21 2001-08-07 Generex Pharmaceuticals Inc. Proteinic drug delivery system using aerosolized membrane-mimetic amphiphiles
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
US20030068361A1 (en) * 2001-10-09 2003-04-10 Rimona Margalit Liposome-encapsulated insulin formulations
ATE496064T1 (de) 2002-05-07 2011-02-15 Novo Nordisk As Lösliche formulierungen, die monomeres insulin und acyliertes insulin enthalten
US8435942B2 (en) * 2002-05-31 2013-05-07 Transdermal Biotechnology, Inc. Methods for formulating stabilized insulin compositions
US20040018237A1 (en) * 2002-05-31 2004-01-29 Perricone Nicholas V. Topical drug delivery using phosphatidylcholine
DE10227232A1 (de) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
US8911751B2 (en) * 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
EP2910569B1 (en) 2008-03-18 2016-10-05 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
CR20170369A (es) 2008-10-17 2017-11-01 Sanofi Aventis Deutschland COMBINACIÓN DE UNA INSULINA Y UN AGONISTA DE GLP-1 (Divisional 2011-0188)
PL2498802T3 (pl) 2009-11-13 2015-06-30 Sanofi Aventis Deutschland Kompozycja farmaceutyczna zawierająca agonistę GLP-1, insulinę i metioninę
WO2011058082A1 (de) 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Pharmazeutische zusammensetzung umfassend einen glp-1-agonisten und methionin
CA2805325C (en) * 2010-07-14 2020-08-04 Yuling Liu Insulin-lipid complex, process for preparation thereof, and formulation thereof
SG187904A1 (en) 2010-08-30 2013-04-30 Sanofi Aventis Deutschland Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
CN103547258B (zh) 2011-03-17 2017-10-20 特兰斯德梅尔生物工艺股份有限公司 局部一氧化氮系统及其使用方法
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
EP2750699B1 (en) 2011-08-29 2015-07-22 Sanofi-Aventis Deutschland GmbH Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US8871257B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery
US8871260B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and compositions for muscular and neuromuscular diseases
US8871258B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment and prevention of learning and memory disorders
US8871254B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system
US8871255B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment of skin and soft tissue infection with nitric oxide
US8871261B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Cancer treatments and compositions for use thereof
US8871256B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and systems for treatment of inflammatory diseases with nitric oxide
US8871262B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Compositions and methods for treatment of osteoporosis and other indications
US8871259B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Techniques and systems for treatment of neuropathic pain and other indications
US9724419B2 (en) 2013-03-13 2017-08-08 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9314433B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9320758B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9241899B2 (en) 2013-03-13 2016-01-26 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9314417B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9393265B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9295637B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US20140271731A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9687520B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9393264B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9314422B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9849160B2 (en) 2013-03-13 2017-12-26 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9750787B2 (en) 2013-03-13 2017-09-05 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US20140271938A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9314423B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US9387159B2 (en) 2013-03-13 2016-07-12 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9295636B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9339457B2 (en) 2013-03-13 2016-05-17 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US20140271937A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
EP3229828B1 (en) 2014-12-12 2023-04-05 Sanofi-Aventis Deutschland GmbH Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
SI3554534T1 (sl) 2016-12-16 2021-09-30 Novo Nordisk A/S Farmacevtski sestavki, ki vsebujejo inzulin
CA3070156A1 (en) 2017-07-20 2019-01-24 Yissum Research Development Company Of The Hebrew University Of Jerusam Ltd. Pharmaceutical film compositions for delivery of lipophilic compounds into and/or across the skin

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2563070A (en) * 1947-12-19 1951-08-07 Chicago Medical School Antidiabetic
GB1285023A (en) * 1968-08-09 1972-08-09 Novo Terapeutisk Labor As Improvements in or relating to injectable insulin preparations
US3758683A (en) * 1971-04-30 1973-09-11 R Jackson Insulin product
JPS50116028A (cs) * 1974-02-26 1975-09-11
JPS5186117A (en) * 1975-01-27 1976-07-28 Tanabe Seiyaku Co Johoseibiryushiseizainoseiho
US4153689A (en) * 1975-06-13 1979-05-08 Takeda Chemical Industries, Ltd. Stable insulin preparation for nasal administration
US4164573A (en) * 1975-06-13 1979-08-14 Galinsky Alvin M Composition and method for making a suppository for introducing a hypoglycemic agent into a mammal
US4086257A (en) * 1976-10-12 1978-04-25 Sears Barry D Phosphatidyl quaternary ammonium compounds
DE2652636A1 (de) * 1976-11-19 1978-05-24 Hans Uwe Dr Rer Nat Wolf Verfahren zur stabilisierung von proteinen und verwandten verbindungen waehrend ihrer reinigung, isolierung und lagerung
CH624011A5 (cs) * 1977-08-05 1981-07-15 Battelle Memorial Institute
CH621479A5 (cs) * 1977-08-05 1981-02-13 Battelle Memorial Institute
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4377567A (en) * 1978-10-02 1983-03-22 The Procter & Gamble Company Lipid membrane drug delivery
DE2952119A1 (de) * 1979-12-22 1981-07-09 Hoechst Ag, 6230 Frankfurt Gegen denaturierung bestaendige, waessrige protein-loesungen
EP0032622B1 (en) * 1979-12-20 1985-08-14 Dennis Chapman Polymerisable phospholipids and polymers thereof, methods for their preparation, methods for their use in coating substrates and forming liposomes and the resulting coated substrates and liposome compositions

Also Published As

Publication number Publication date
SE8206168L (sv) 1983-05-01
DE3240177C2 (cs) 1993-07-22
US4614730A (en) 1986-09-30
NL193099C (nl) 1998-11-03
ES516963A0 (es) 1984-03-01
DE3240177A1 (de) 1983-05-11
GR77360B (cs) 1984-09-11
IE822602L (en) 1983-04-30
AU8986182A (en) 1983-05-05
FR2515517A1 (fr) 1983-05-06
GB2107985B (en) 1984-11-14
PT75766B (en) 1985-12-09
IE54029B1 (en) 1989-05-24
PT75766A (en) 1982-11-01
IT1153315B (it) 1987-01-14
FI80595B (fi) 1990-03-30
NL193099B (nl) 1998-07-01
GB2107985A (en) 1983-05-11
NL8203944A (nl) 1983-05-16
NO823603L (no) 1983-05-02
FI823702L (fi) 1983-05-01
CA1198673A (en) 1985-12-31
FI823702A0 (fi) 1982-10-29
BE894885A (fr) 1983-04-29
AU549593B2 (en) 1986-01-30
LU84447A1 (fr) 1983-06-13
ES8403025A1 (es) 1984-03-01
NZ202328A (en) 1985-07-12
IT8223990A0 (it) 1982-10-29
FR2515517B1 (fr) 1987-07-03
CH649922A5 (de) 1985-06-28
ATA392482A (de) 1986-06-15
NO168086C (no) 1992-01-15
AT382079B (de) 1987-01-12
FI80595C (fi) 1990-07-10
NO168086B (no) 1991-10-07
SE8206168D0 (sv) 1982-10-29

Similar Documents

Publication Publication Date Title
SE460576B (sv) Mot graensskiktspolymerisation med hjaelp av fosfolipid stabiliserad insulinpreparation
CA1064396A (en) Fractional precipitation of gamma globulin with polyethylene glycol
US4165370A (en) Injectable gamma globulin
SE460948B (sv) Med zinkjoner stabiliserad insulinloesning samt foerfarande foer dess framstaellning
SE509295C2 (sv) Insulinanalog-protamin-komplex
NZ256413A (en) Medicaments which form a gel in vivo comprising a lecithin, a water-insoluble solvent and an active agent
KR920002934B1 (ko) 내변성 단백질 수용액의 제조방법
FI80596C (fi) Foerfarande foer framstaellning av en mot mekaniska belastningar stabiliserad vattenhaltig insulinberedning och anvaendning av ett fysiologiskt godtagbart fortjockningsmedel och en aktiv substans foer stabilisering av vattenhaltiga insulinpreparat.
KR20040018458A (ko) Ｃｅｔｕｘｉｍａｂ 및 폴리옥시에틸렌 소르비탄 지방산에스테르를 포함하는 액형 제제
AU679012B2 (en) Process for manufacturing crystals of growth hormone and crystals thereby obtained
AU737595B2 (en) Lyophilized composition of bone morphogenetic factor human MP52
AU602715B2 (en) Freeze-dried pharmaceutical compositions
KR20210056349A (ko) 단백질 및 폴리알콕시 지방 아실 계면활성제를 포함하는 조성물
JP2001519390A (ja) 安定剤としてグリシンを含む製薬学的製剤
JPH0366291B2 (cs)
JP6965474B1 (ja) テリパラチド又はその塩を含有するプレフィルドシリンジまたはカートリッジ製剤の振盪による白濁を抑制する方法
EP0561141A1 (en) Highly concentrated amino acid solution
DK152832B (da) Fremgangsmaade til fremstilling af en vandig insulinoploesning, der er fysisk stabiliseret mod graensefladepolymerisation
CN1183727A (zh) 防止血小板生成素(tpo)吸附的方法及含tpo的稳定组合物
RU2261108C2 (ru) Способ получения комбинированного препарата инсулина человека
US20160095904A1 (en) Stabilized liquid formulation
HK1013299B (en) Process for manufacturing crystals of growth hormone and crystals thereby obtained
JPS6399022A (ja) 静脈内投与に適したガンマ・グロプリン

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 8206168-0

Format of ref document f/p: F

NUG Patent has lapsed

Ref document number: 8206168-0

Format of ref document f/p: F